Syngene International Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mqg4bmxr66id243k0w19jwrt.pdf

Key Takeaways


The Zoetis Deal

Hunt: "A recent highlight was the signing of a 10-year agreement with Zoetis. The new agreement initially focuses on the commercial manufacturing of Librela®, a first-of-its-kind injectable monoclonal antibody used for the alleviation of pain associated with osteoarthritis in dogs. This is a major strategic step for our biologics business and gives us a pathway towards FDA and EMA regulatory approvals anticipated later this year."

Revenue & Profitability

Hunt: "These first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. ... The decline in profit in the quarter compared to the same period last year was as expected given the strong sales of Remdesivir last year when India was in the midst of the second wave of the pandemic. No sales of Remdesivir were recorded in the first quarter this year."

Divisional Performance


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthRaised from mid-teens to high teens, driven by rupee depreciation and the Zoetis agreementFY23
Zoetis revenue contributionRevenue from Librela® commercial manufacturing to begin, subject to regulatory approvalsH2 FY23
Zoetis regulatory approvalsFDA and EMA approvals for Librela® anticipatedLater in 2022
Zoetis future moleculesAgreement paves the way for development and manufacturing of other moleculesComing years
Biswas: "Revenue guidance for the year has been raised from mid-teens to high teens to account for two factors: a significant change in the Rupee/US dollar exchange rate which helps the top line as most of our client contracts are dollar denominated and the recent agreement with Zoetis, which will start to benefit revenue in the second half of the year and build gradually in future years."

Key Metrics

MetricQ1 FY23
Revenue from operations₹644 Cr, +8% YoY
Total revenue₹660 Cr, +9% YoY
Underlying revenue growth (ex-Remdesivir)~30% YoY
EBITDA₹188 Cr, +6% YoY
EBITDA margin28.5%, vs 29.2% in Q1 FY22
PAT₹74 Cr, -4% YoY
PAT margin11%, vs 13% in Q1 FY22
EPS (basic)₹1.85
Staff costs₹186 Cr, +9% YoY
Other expenses₹103 Cr, +57% YoY
Annual revenue growth guidanceHigh teens, raised from mid-teens
Zoetis agreement valueUp to US$500 Mn over 10 years, subject to regulatory approvals and market demand
ScientistsMore than 5,200